Form 4 for CRL Charles River Laboratories
Accepted 2022-05-04 00:00:00 ET · period of report 2022-05-02 · accession 0001127602-22-013202 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-05-04 | 2022-05-02 | CRL | Pease Flavia | Corp. Executive VP | A - Grant | $0.00 | +5,185 | 5,185 | New | $0 |
| D | 2022-05-04 | 2022-05-02 | CRL | Pease Flavia | Corp. Executive VP | A - Grant | $245.88 | +4,649 | 4,649 | New | +$1.14M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-05-02 | A | A | 5,185 | $0.00 | 5,185 | D | — | — | (F1) Unvested restricted stock units vest as follows: 2,592 on May 02, 2024, and 2,593 on May 02, 2025. |
| 2 | Derivative | Stock Options (Right to Buy) | 2022-05-02 | A | A | 4,649 | $245.88 | 4,649 | D | $245.88 · 2024-05-02 to 2032-05-02 | 4,649 Common Stock | (F2) Stock Options vest as follows: 2,324 on May 02, 2024, and 2,325 on May 02, 2025. |